AnaCardio Announces Phase 1b/2a GOAL-HF1 Results of AC01 Demonstrating Favorable Safety and Sustained Improvements in Cardiac Function on Top of Standard-of-Care Therapy in HFrEF at Late-Breaking Session at HFA 2026
STOCKHOLM, Sweden, May 11, 2026 – AnaCardio today announced detailed results from its Phase 1b/2a GOAL-HF1 study evaluating AC01 in patients with heart failure with reduced ejection fraction (HFrEF), presented in a Late-Breaking Science session at the European Society of Cardiology (ESC) Heart Failure Association (HFA) Congress 2026 in Barcelona, Spain. The randomized, double-blind, placebo-controlled […]